Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #153153 on Biotech Values
DonShimoda
11/28/12 10:41 AM
#153154 RE: caravon #153153
there are still 4 Tivantinib clinical trials are going including Marquee
it is too early to discuss Roche's Metmab 1st-to-market NSCLC advantage
They could easily enroll and complete the trial in under 2 years but they are not rushing...